An August 2021 appraisal of therapeutic-dose heparin in hospitalised COVID-19 patients without ICU-level organ support. It examines the multiplatform trial’s benefits, bleeding-risk exclusions and composite outcome, and explains why these findings differ from those in critically ill patients.